Veraxa Biotech Holding AG (FRA:J8L0) EBIT: €-71.60 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J8L0 Veraxa Biotech Holding AG FRA:J8L0
13 GF Score
Price €1.62
! 2 Warning Signs
View Full Analysis

What is Veraxa Biotech Holding AG EBIT?

Veraxa Biotech Holding AG FRA:J8L0 -2.06% 13 EBIT is €-71.60 Mil as of Dec. 2025. GuruFocus rates FRA:J8L0 with a GF Score™ of 13/100. The stock has 2 warning signs investors should review.

Veraxa Biotech Holding AG's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €-32.30 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-71.60 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Veraxa Biotech Holding AG's annualized ROC % for the quarter that ended in Dec. 2025 was -72.88%. Veraxa Biotech Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -2,047.08%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Veraxa Biotech Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -32.88%.

Veraxa Biotech Holding AG  (FRA:J8L0) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Veraxa Biotech Holding AG's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-63.778 * ( 1 - 0.5% )/( (85.534 + 88.623)/ 2 )
=-63.45911/87.0785
=-72.88 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=87.689 - 1.519 - ( 3.534 - max(0, 3.528 - 4.164+3.534))
=85.534

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=86.611 - 1.984 - ( 1.73 - max(0, 7.088 - 3.092+1.73))
=88.623

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Veraxa Biotech Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-64.606/( ( (2.981 + max(-3.06, 0)) + (3.331 + max(-5.633, 0)) )/ 2 )
=-64.606/( ( 2.981 + 3.331 )/ 2 )
=-64.606/3.156
=-2,047.08 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.302) - (1.519 + 0.947 + 0.896)
=-3.06

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.108) - (1.984 + 1.101 + 2.656)
=-5.633

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Veraxa Biotech Holding AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-71.602/217.778
=-32.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veraxa Biotech Holding AG EBIT Related Terms

Veraxa Biotech Holding AG EBIT Historical Data

* Premium members only.

The historical data trend for Veraxa Biotech Holding AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veraxa Biotech Holding AG EBIT Chart

Veraxa Biotech Holding AG Annual Data
Trend Dec23 Dec24 Dec25
EBIT
-18.72 -30.80 -71.80

Veraxa Biotech Holding AG Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
EBIT 0.00 -10.59 -19.88 -39.30 -32.30

FRA:J8L0 vs TTRX, IRD, IFRX: EBIT Comparison

For the Biotechnology subindustry, Veraxa Biotech Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Veraxa Biotech Holding AG EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Veraxa Biotech Holding AG's EV-to-EBIT falls into.


FRA:J8L0
13GF Score
Veraxa Biotech Holding AG FRA:J8L0
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veraxa Biotech Holding AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-71.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-71.60 Mil mean?
Veraxa Biotech Holding AG (FRA:J8L0) has a EBIT of €-71.60 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Veraxa Biotech Holding AG.
Is Veraxa Biotech Holding AG's EBIT too high?
Veraxa Biotech Holding AG's current EBIT is €-71.60 Mil. Overall, Veraxa Biotech Holding AG has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's EBIT compare to TTRX and IRD?
Veraxa Biotech Holding AG's EBIT of €-71.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Veraxa Biotech Holding AG. Veraxa Biotech Holding AG's current EBIT is €-71.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (FRA:J8L0) has a current EBIT of €-71.60 Mil. The current EBIT is €-71.60 Mil. Veraxa Biotech Holding AG's overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Veraxa Biotech Holding AG (FRA:J8L0), the current EBIT is €-71.60 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veraxa Biotech Holding AG Business Description

Other Exchanges VRXA:USA
Address Talacker 35, Zurich, CHE, 8001
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
13GF Score

Get the complete analysis for FRA:J8L0

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.62
Price